Therapeutic applications such as cardiology, oncology, neurological disorder, and pain management will keep the global Pharmacogenomics Market in good stead in the near future.

Rising usage of Pharmacogenomics in drug discovery processes, prevalence of various infectious as well as non-infectious diseases, growing demand for personalized drugs, and increasing awareness regarding the benefits of customized medication are some of the key factors augmenting the demand in the global pharmacogenomics market. The concept of pharmacogenomics has the ability to serve subpopulations on the basis of susceptibility to particular disease, as individual response of a drug depends on genetic composition. Rise in investment in research and development and advancement in technology pharmacogenomics engineering to create in vivo environment are some of the other factors favoring the global pharmacogenomics market. Some of the drugs used for pharmacogenomics tests are thiopurines, warfarin, clopidogrel, abacavir, irinotecan, phenytoin, and carbamazepine. These tests are useful for diseases such as autoimmune or childhood leukemia, excessive clotting disorder, cancer, cardiovascular, HIV, psychiatric and related diseases, and epilepsy.

On the other hand, the lack of consistency in pharmacogenomics products is one of the major hindrance of the expansion of the market. Nevertheless, the vendors operating in the pharmacogenomics market are expected to gain from increased focus on regenerative medicine and increased awareness of organ transplantation.

Technology-wise, the global pharmacogenomics market can be segmented into sequencing such as sanger sequencing, pyrosequencing, and next-generation sequencing, polymerase chain reaction, and other technologies such as electrophoresis and mass spectrometry. In the current scenario of the market, sequencing dominates the market, particularly since the advent of next generation sequencing, which offers high accuracy, increased throughput screening, and speed. Application-wise, the market can be bifurcated into oncology, pain management, cardiology, and neurological disorders.

Geographically, the report studies the potential of pharmacogenomics market in every major region such as North America, Asia Pacific, Europe, and the Middle East and Africa. Currently, North America is most profitable region, gaining most of the demand from the developed countries of the U.S. and Canada. However, Asia Pacific is also expected to increment the demand steadily during the forecast period due to improving healthcare facilities in a number of emerging economies.

Some of the most prominent players operating in the global pharmacogenomics market are GE Healthcare, GlaxoSmithKline, GeneDX, Pfizer, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Abbott Laboratories, Inc., Assurex Health, Affymetrix, Inc., Bayer AG, Illumina, Inc., Merck & Co, Myriad Genetics, Inc., Johnson & Johnson, Pathway Genomics, Teva Pharmaceutical Industries Ltd, Qiagen, Inc., and Thermo Fisher Scientific.

Download a PDF Brochure ofPharmacogenomics Market Research Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3615

Go here to read the rest:
Pharmacogenomics Market: Improving Healthcare Infrastructure in APAC Incrementing Demand - Edition Truth